HOME >> MEDICINE >> NEWS
Researchers identify brain pathway to explain how Fenfluramine causes weight loss

BOSTON Scientists have identified the molecular pathway in the brain that helps explain how the once-popular diet drug d-Fenfluramine (d-FEN) works to promote weight loss, a discovery reported in the July 26 issue of Science that could provide an opportunity to develop a new anti-obesity treatment without d-FEN's cardiac side effects.

The study, led by a team of researchers at Beth Israel Deaconess Medical Center (BIDMC), also suggests this same brain pathway the melanocortin system is responsible for regulation of body weight at either end of the weight spectrum from obesity at one extreme to anorexia nervosa at the other.

D-FEN, used in combination with phenteramine and known as fen-phen, was banned by the U.S. Food and Drug Administration (FDA) in 1997 after a subset of patients taking the drug developed cardiac complications.

"This study helps close the circle on the role of the melanocortin pathway and adds the serotonin system to the growing list of metabolic signals including leptin that act on the brain's melanocortin neurons, regulating food intake and body weight," explains the study's senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at BIDMC and associate professor of endocrinology and medicine at Harvard Medical School.

The diet drug d-FEN, which is the "fen" part of the fen-phen combination, first came on the market in 1992, and within five years, had been prescribed to millions of individuals who were trying to lose weight. The drug works by increasing the brain's release of serotonin, a "chemical messenger" that, among other things, helps to suppress appetite. Serotonin acts as a neurotransmitter to convey nerve impulses in the brain, and anti-obesity drugs such as fenfluramine, as well as the popular antidepressant medications fluoxetine (Prozac) and sertraline (Zoloft) work by enhancing this effect.

However, as Elmquist explains, d-FEN's popularity was relatively brief:
'"/>

Contact: Bonnie Prescott
bprescot@caregroup.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
25-Jul-2002


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased ... is the first sweetFrog store located in Mississippi. The premium frozen yogurt chain was ... , The store, located at 104 Railroad Avenue, New Albany, MS 38652, will have ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the ... July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy 64, Suite 200, ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ... her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June ... (D-R.I.), this Act seeks to decrease drug overdose – especially of heroin and ...
(Date:7/2/2015)... ... July 02, 2015 , ... Many Fourth of July celebrations will ... Amica Insurance is sharing some tips to promote the proper use of ... go to the emergency room daily with fireworks-related injuries in the month surrounding the ...
(Date:7/2/2015)... ... ... Achebe realized that the gift of poetry was fully in him, as beautiful phrases riddled ... three years later he was publishing an entire book of poetry. He knew there was ... always believed that the best way to lift yourself up, is in the effort of ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
(Date:7/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) ... Technology, Imaging and by Application - Forecast to 2020" report ... expected to reach $13.1 Billion in 2020 from an estimated $7.1 ... The market is dominated by North America , ... , and Rest of the World (RoW). The cancer diagnostics market ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
(Date:7/2/2015)... Mass. , and DURHAM, N.C. ... , Inc. today announced its acquisition of assets related ... (NYSE: PFE ) that had previously been obtained ... XRPro Sciences also acquired all of Pfizer,s rights to ... the Icagen brand and will provide comprehensive services for ...
Breaking Medicine Technology:Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Numotion Names Tamas Feitel Chief Financial Officer 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
Cached News: